Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Systems Immunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1478107
This article is part of the Research Topic Computational Vaccine Development Against Parasites View all 16 articles

Exploring glutathione transferase and Cathepsin L-like proteinase for designing of epitopes based vaccine against Fasciola hepatica by immunoinformatics and biophysics studies

Provisionally accepted
  • 1 College of Applied Medical Sciences, Al Jouf University, Sakaka, Saudi Arabia
  • 2 Jouf University, Sakakah, Al Jawf, Saudi Arabia
  • 3 King Saud University, Riyadh, Riyadh, Saudi Arabia
  • 4 Ministry of Health (Saudi Arabia), Riyadh, Riyadh, Saudi Arabia

The final, formatted version of the article will be published soon.

    Fasciolosis is a zoonotic infection and is considered a developing deserted tropical illness threatening ruminant productivity and causing financial losses. Herein, we applied immunoinformatics and biophysics studies to develop an epitopes vaccine against Fasciola hepatica using glutathione transferase and Cathepsin L-like proteinase as possible vaccine candidates. Using the selected proteins, B-cell and T-cell epitopes were predicted. After epitopes prediction, the epitopes were clarified over immunoinformatics screening and only five epitopes, EFGRWQQEKCTIDLD,RRNIWEKNVKHIQEH,FKAKYLTEMSRASDI, TDMTFEEFKAKYLTE and YTAVEGQCR were selected for vaccine construction, selected epitopes were linked with the help of GPGPG linker and attached with adjuvant through another linker EAAAK linker, Cholera toxin B subunit was used as an adjuvant, The expasy protparam tool the server predicted 234 amino acids, 25.86257-kilo dalton molecular weight, 8.54 Theoretical pI, 36.86 instability index and -0.424 Grand average of hydropathicity. Molecular docking analysis predicted the vaccine could activate the immune system against F. hepatica. We calculated negative binding energy values. A biophysics study, likely molecular docking molecular dynamic simulation, further validated the docking results. In molecular dynamic simulation analysis, the top hit docked compounds with the lowest binding energy values were subjected to MD simulation; the simulation analysis showed that the vaccine and immune cell receptors are stable and can activate the immune system. MMGBSA -146.27 Net Energy (kcal/mol) was calculated for the vaccine-TLR-2 complex while vaccine-TLR-4 -148.11, Net Energy (kcal/mol) was estimated. Further, the C-ImmSim bioinformatics tool predicted that the vaccine construct can activate the immune system against F. hepatica, eradicate the infection caused by F. hepatica, and reduce financial losses that need to be spent while protecting against infections of F. hepatica. The computational immune simulation unveils that the vaccine model can activate the immune system against F. hepatica; hence, the experimental scientist can validate the finding accomplished through computational approaches.

    Keywords: Fasciola hepatica, immunoinformatics, Epitopes, molecular docking, MD simualtion

    Received: 09 Aug 2024; Accepted: 28 Aug 2024.

    Copyright: © 2024 Alhassan, Ullah, Niazy, Alzarea, Alsaidam, Alzarea, Alsaidan, Alhassan, Alruwaili and Alruwaili. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hassan Alhassan, College of Applied Medical Sciences, Al Jouf University, Sakaka, Saudi Arabia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.